NCT02375464

Brief Summary

Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2015

Longer than P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 24, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 2, 2015

Completed
1 month until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

November 8, 2016

Status Verified

November 1, 2016

Enrollment Period

3.7 years

First QC Date

February 24, 2015

Last Update Submit

November 4, 2016

Conditions

Neuroendocrine Tumors

Keywords

neuroendocrine tumorcarcinoid tumor

Interventions

Gallium-68 DOTATOCDRUG

Imaging with Gallium-68 DOTATOC

Also known as: Gallium-68 (DOTA0-Phe1-Tyr3)octreotide

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Proven or suspected neuroendocrine tumor Physician referral for imaging

You may not qualify if:

  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Neuroendocrine TumorsCarcinoid Tumor

Interventions

Ga(III)-DOTATOCGallium-68

Condition Hierarchy (Ancestors)

Neuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueAdenocarcinomaCarcinomaNeoplasms, Glandular and Epithelial

Study Officials

  • STEPHEN C SCHARF, MD

    Lenox Hill Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
expanded access
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 24, 2015

First Posted

March 2, 2015

Study Start

April 1, 2015

Primary Completion

December 1, 2018

Study Completion

December 1, 2019

Last Updated

November 8, 2016

Record last verified: 2016-11